David A. Frey
Lawyers
Associate in our IP & Tech Transactions practice.
Experience highlights
Recent Representations
- Nayax direct listing
- Tenaya Therapeutics $75 million at-the-market offering
- RxSight $50 million at-the-market offering
- Infinera $373.75 million convertible senior notes offering
- Legend Biotech $403 million follow-on offering
- Baker Hughes sale of Nexus Controls to GE Gas Power
- GSK $3.3 billion acquisition of Affinivax
- SiTime at-the-market offering
- Acutus Medical sale of its left-heart access portfolio products
- Owens & Minor $600 million notes offering
- AN2 Therapeutics $69 million IPO
- Novo Nordisk $3.3 billion acquisition of Dicerna Pharmaceuticals
- TBCASoft $25 million Series B equity funding round
- Adagio Therapeutics $356 million IPO
- RxSight $117.6 million IPO
- Tenaya Therapeutics $207 million IPO
Education
J.D., Georgetown University Law Center
- Senior Editor, Georgetown Law Technology Review
B.S., Chemical Engineering, Bucknell University
Professional history
- Davis Polk since 2021
Qualifications and admissions
- State of New York